Quality of life scores should be compared before and after patients have undergone dialysis
To the Editor: We intentionally read the article "Quality of life (QoL) in hemodialysis and peritoneal dialysis patients in Saudi" written by Wakeel et al with great interest. 1 They concluded that the quality of life (QoL) was better among peritoneal dialysis (PD) than hemodialysis (HD) patients in all domains except physical domain. PD patients spent more quality time and were more satisfied than HD patients. 1 In the last years, advances in dialysis procedures and new guidelines to treat the chronic renal failure patients have improved their treatment and prolonged their lives. At the same time, the concept of health-related quality of life (HRQoL) strengthened as a new goal to be achieved. The current dialysis guidelines enforce treatments to achieve similar outcomes in the long run, independently of the choice of dialysis treatment. 2 Manns et al. in their study concluded that there was no significant difference in HRQoL for prevalent end-stage renal disease patients treated with HD or PD. 3 In another study, Wu et al. concluded that that PD did not seem to produce a better QoL than HD for patients who imitated renal replacement therapy. 4 Ginieri-Coccossis. et al. in their study concluded that the results provided evidence that patients in HD treatment modality, particularly those with many years of treatment, experienced a more compromised QoL in comparison to PD patients. 5 The results may change due to sociodemographic characteristics of patients. We think that the comparison of the two groups could be more meaningful if the QoL is measured before and after patients are undergone dialysis. Another point of discussion could be that the variations in study results may vary upon longer follow-up durations of these patients. 1 In an experimental study on 48 male Wistar albino rats, Elberry et al. aimed to study the ameliorative effects of oxytocin against cisplatin renal toxicity. 1 They assessed the renal injury of cisplatin by performing histopathological study and by observing an increase in serum LDH activity as well as urea and creatinine levels. Furthermore, to asses renal injury, they also measured renal tissue activities of catalase, superoxide dismutase, glutathione peroxidase, and glutathione S-transferase as well as glutathione level. Also the renal tissue content of thiobarbituric acid-reactive substances, nitric oxide end-product nitrite, and the activity of myeloperoxidase were measured. They found that oxytocin protected rats from cisplatin-induced nephrotoxicity and attributedthis to the antioxidant activity of oxytocin. 1 In this letter, I would like to point out a few points about cisplatin nephrotoxicity. In a preclinical study, we observed that estrogen attenuates the defending property of erythropoietin against cisplatin-induced renal toxicity in ovariectomized Wistar rats. 2 We also observed that L-arginine had ameliorative effects against cisplatin-induced renal toxicity in male rats. Nevertheless, it intensifies the induced injury in female rats. 3 In this study, we described a sexrelated difference in the rat model of cisplatin nephrotoxicity. 3 Since, the position of gender in cispla-tin-induced renal toxicity is not reported from published reports, we conducted another preclinical study on the rat model of cisplatin nephrotoxicity. From the results of this study we found that losartan, as an angiotension receptor blocker, may prevent cisplatin nephrotoxicity in males, whereas it aggravates the cisplatin-induced tubular injury in female rats. 4 We concluded that the sex-related difference of cisplatin nephrotoxicity may be related to the renin-angiotensin system receptors in the kidneys. [4] [5] [6] [7] [8] [9] In addition, we reported that, Vitamin E, Vitamin C, or losartan have not ameliorative effects against cisplatin-induced renal toxicity in the presence of estrogen in the ovariectomized rat model of cisplatin toxicity, 10 which is in agreement with our previous results. Therefore, it is well established that there is a gender difference in the cisplatin-induced renal toxicity in the rat model. However, it is well recognized that some conditions leading to chronic kidney diseases are gender related too. [5] [6] [7] [8] [9] Few studies published regarding gender difference in cisplatin-induced kidney toxicity. However, there still needs to more investigate mechanisms interact in cisplatin nephrotoxicity especially on gender difference. 10, 11 To better find the factor of sex difference in cisplatin nephrotoxicity, further experimental rat model or clinical studies recommended.
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The authors declared no competing interests. 1 The authors skillfully declared an interesting investigation about the benefits of intrauterine balloon splinting/ Foley catheter after resectoscopic septum division on fertility, septum reformation, and pregnancy outcomes. They concluded that "Following resectoscopic septum division with monopolar knife electrode, splinting the uterine cavity with Foley catheter provided no advantage in clinical pregnancy rate, septum reformation, and pregnancy outcomes." Although this issue is a challenging topic in fertility and pregnancy, but there are some concerns in the mentioned study that undermine the reported findings to make a definite conclusion.
Hamid nasri
The number of cases included in the study is one of the most discussed queries. I can declare that if the difference between the 2 studied groups (balloon or no balloon) was not significant, it could due to the small amount of sample size that did not allow drawing any definitive conclusions. Thus, to rule out this query and to compensate any refusal of data, the authors should estimate the "power" of their study. The authors randomized the pa-RefeRences tients into the 2 studied groups, and no significant difference in terms of age, parity, and comorbidities were reported. However, menopausal status, race, age of menopause, menopausal hormone therapy, occupation, marital status, OCP use, and so on, should be distributed equally between the 2 groups before drawing any conclusion, which was not considered by the authors in this study.
The authors expertly excluded those patients who received preoperative endometrial thinning, adjunctive postoperative hormone therapy, or antibiotic prophylaxis, but they seemed to be inadequate as exclusion criteria in the clinical study. The authors did not declare if they excluded pregnant women, patients with active pelvic infection, patients allergic to radiographic contrast media, and patients with or without known endometrial or cervical cancer.
2,3 Therefore, the mentioned criteria should be considered by the authors. A participation fellow chart is mandatory for clinical studies based on the CONSORT (Consolidated Standards of Reporting Trials) statement, 4, 5 but it was missing in this study. Moreover, in the "Methods" section, the statistical analysis is poorly presented and the power analysis is incomplete. Moreover, the chosen proportion for significant or not significant difference in fertility and pregnancy outcomes should be mentioned. Finally, the secondary outcomes of the resectoscopic procedure, such as fever, increasing abdominal pain, heavy vaginal bleeding, foul smelling vaginal discharge, 6 and so on, should be mentioned in the results by the authors.
We suggest that a study with accurate and powerful methods according to CONSORT statement is required for this topic. However, the authors acknowledged to the heterogeneity of their study population as a limitation. Therefore, future studies with a homogeneous sample, well-characterized controls, and cases that increase the sensitivity of detecting the associations should be considered necessary to exclude this problem.
Prevalence of celiac disease in healthy Iranian school children
To the Editor: I have two comments on the interesting study by Dehghani et al. 1 First, Dehghani et al 1 stated in their study that the prevalence of celiac disease (CD) based on antitissue transglutaminase antibodies (tTGA) screening test was 1:50, whereas the prevalence of biopsyproven CD (silent celiac) was 1:167. I presume that the actual prevalence is higher. This is based on the following contributory factors: (1) The consumption of wheat as a major dietary staple is still a major custom in Iran. (2) Consanguineous marriage is a prevailing practice in Iran with the first cousin marriage being the most common type of consanguinity (69%). are not yet present on HLA phenotypes in Iranians, the available data has pertained to the potential role of HLA-DQ2 in increasing the propensity of certain populations in Asia like Iran to have CD. 3 (7) Iranians might follow the general trend of overall worldwide increase in the CD prevalence, including silent cases.
Second, to meet the principles of screening, a disease must be common, and a significant health burden must be detectable and treatable. I presume that screening for CD in Iranian children seems justi-RefeRences fiable. This is based on the following points: (1) There is substantial prevalence of CD, in particular, silent cases in Iran. 1, 4 (2) Undiagnosed CD patients have long-term serious health consequences, including malignancy, anemia, short stature, osteopenia, and infertility. Moreover, the medical costs and utilization of selected health care services over time for symptomatic CD patients during the delay between symptoms onset and diagnosis are substantial. (3) There is the presence of effective screening tool for CD in terms of measuring the serum tTGA supplemented whenever necessary by small intestinal biopsy. (4) There is the presence of effective therapy for CD in terms of gluten-free diet. The children' s age range supposed to undergo screening for CD ought to be determined in Iran. However, the available evidence has advocated the age 2 to 3 years as the best time for measuring the serum tTGA due to the high detection rate.
